Literature DB >> 28185222

Trimethoprim-sulfamethoxazole therapy for patients with carbapenemase-producing Klebsiella pneumoniae infections: retrospective single-center case series.

Rita Murri1, Barbara Fiori2, Teresa Spanu2, Ilaria Mastrorosa2, Francesca Giovannenze2, Francesco Taccari2, Claudia Palazzolo2, Giancarlo Scoppettuolo2, Giulio Ventura2, Maurizio Sanguinetti2, Roberto Cauda2, Massimo Fantoni2.   

Abstract

OBJECTIVE: The objective of the study was to evaluate the efficacy and tolerability of trimethoprim-sulfamethoxazole (also known as co-trimoxazole, TMPS) to treat Klebsiella pneumoniae (Kp)-K. pneumoniae carbapenemase (KPC) infections.
METHODS: Clinical data of patients with a TMPS-susceptible Kp-KPC infection were collected as a case series.
RESULTS: We report clinical outcomes and tolerability for 14 patients infected by Kp-KPC strains susceptible to TMPS, including three bloodstream infections. In ten cases (71.4%), TMPS was administered as monotherapy. In all but one case, Kp-KPC infection was cured. In the remaining patient, therapy was discontinued because of an adverse event.
CONCLUSIONS: The use of TMPS to treat TMPS-susceptible Kp-KPC infections seems promising.

Entities:  

Keywords:  Carbapenemase; Co-trimoxazole; KPC; Multidrug-resistant infections; Trimethoprim–sulfamethoxazole

Mesh:

Substances:

Year:  2017        PMID: 28185222     DOI: 10.1007/s15010-016-0968-x

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  24 in total

1.  Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.

Authors:  Antonio T Freire; Vasyl Melnyk; Min Ja Kim; Oleksiy Datsenko; Oleksandr Dzyublik; Felix Glumcher; Yin-Ching Chuang; Robert T Maroko; Gary Dukart; C Angel Cooper; Joan M Korth-Bradley; Nathalie Dartois; Hassan Gandjini
Journal:  Diagn Microbiol Infect Dis       Date:  2010-10       Impact factor: 2.803

2.  Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.

Authors:  Mario Tumbarello; Enrico Maria Trecarichi; Francesco Giuseppe De Rosa; Maddalena Giannella; Daniele Roberto Giacobbe; Matteo Bassetti; Angela Raffaella Losito; Michele Bartoletti; Valerio Del Bono; Silvia Corcione; Giuseppe Maiuro; Sara Tedeschi; Luigi Celani; Chiara Simona Cardellino; Teresa Spanu; Anna Marchese; Simone Ambretti; Roberto Cauda; Claudio Viscoli; Pierluigi Viale
Journal:  J Antimicrob Chemother       Date:  2015-04-21       Impact factor: 5.790

3.  Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.

Authors:  Jesús Oteo; Adriana Ortega; Rosa Bartolomé; Germán Bou; Carmen Conejo; Marta Fernández-Martínez; Juan José González-López; Laura Martínez-García; Luis Martínez-Martínez; María Merino; Elisenda Miró; Marta Mora; Ferran Navarro; Antonio Oliver; Álvaro Pascual; Jesús Rodríguez-Baño; Guillermo Ruiz-Carrascoso; Patricia Ruiz-Garbajosa; Laura Zamorano; Verónica Bautista; María Pérez-Vázquez; José Campos
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

Review 4.  Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria.

Authors:  M Akova; G L Daikos; L Tzouvelekis; Y Carmeli
Journal:  Clin Microbiol Infect       Date:  2012-05       Impact factor: 8.067

5.  IMP-producing carbapenem-resistant Klebsiella pneumoniae in the United States.

Authors:  Brandi M Limbago; J Kamile Rasheed; Karen F Anderson; Wenming Zhu; Brandon Kitchel; Nancy Watz; Susan Munro; Hayley Gans; Niaz Banaei; Alex J Kallen
Journal:  J Clin Microbiol       Date:  2011-10-12       Impact factor: 5.948

6.  Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.

Authors:  Zubair A Qureshi; David L Paterson; Brian A Potoski; Mary C Kilayko; Gabriel Sandovsky; Emilia Sordillo; Bruce Polsky; Jennifer M Adams-Haduch; Yohei Doi
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

7.  Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.

Authors:  Elizabeth A Neuner; Jun-Yen Yeh; Gerri S Hall; Jennifer Sekeres; Andrea Endimiani; Robert A Bonomo; Nabin K Shrestha; Thomas G Fraser; David van Duin
Journal:  Diagn Microbiol Infect Dis       Date:  2011-04       Impact factor: 2.803

8.  KPC-producing Klebsiella pneumoniae strains that harbor AAC(6')-Ib exhibit intermediate resistance to amikacin.

Authors:  Derek N Bremmer; Cornelius J Clancy; Ellen G Press; Reem Almaghrabi; Liang Chen; Yohei Doi; M Hong Nguyen; Ryan K Shields
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

9.  Outbreak of infections due to KPC-2-producing Klebsiella pneumoniae in a hospital in Crete (Greece).

Authors:  H C Maltezou; P Giakkoupi; A Maragos; M Bolikas; V Raftopoulos; H Papahatzaki; G Vrouhos; V Liakou; A C Vatopoulos
Journal:  J Infect       Date:  2009-02-26       Impact factor: 6.072

10.  Emergence of Carbapenem-Resistant Klebsiella pneumoniae: Progressive Spread and Four-Year Period of Observation in a Cardiac Surgery Division.

Authors:  Fortunata Lombardi; Paola Gaia; Rea Valaperta; Maria Cornetta; Milvana Rosa Tejada; Luca Di Girolamo; Alessandra Moroni; Federica Ramundo; Alessio Colombo; Massimiliano Valisi; Elena Costa
Journal:  Biomed Res Int       Date:  2015-05-04       Impact factor: 3.411

View more
  4 in total

1.  Antagonistic effect between tigecycline and meropenem: successful management of KPC-producing Klebsiella pneumoniae infection.

Authors:  Sheng Bi; Xin Yao; Cheng Huang; Xia Zheng; Tianming Xuan; Jifang Sheng; Kaijin Xu; Beiwen Zheng; Qing Yang
Journal:  Infection       Date:  2019-02-07       Impact factor: 3.553

2.  A challenging case of carbapenemase-producing Klebsiella pneumoniae septic thrombophlebitis and right mural endocarditis successfully treated with ceftazidime/avibactam.

Authors:  Alessandra Iacovelli; Martina Spaziante; Samir Al Moghazi; Alessandra Giordano; Giancarlo Ceccarelli; Mario Venditti
Journal:  Infection       Date:  2018-06-20       Impact factor: 3.553

Review 3.  Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae.

Authors:  Jesús Rodríguez-Baño; Belén Gutiérrez-Gutiérrez; Isabel Machuca; Alvaro Pascual
Journal:  Clin Microbiol Rev       Date:  2018-02-14       Impact factor: 26.132

Review 4.  How to manage KPC infections.

Authors:  Matteo Bassetti; Maddalena Peghin
Journal:  Ther Adv Infect Dis       Date:  2020-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.